Clinical trials: Hyperinsulinemia
Insulin Sensitivity/Resistance
Assessment of Insulin Sensitivity in Healthy Adults by a 13C-glucose Breath Test : Method Development and Validation
The current research project aims to assess the insulin resistance (less sensitivity), from measures of insulin and glucose in response to a standard oral intake of glucose (standardized oral glucose tolerance test).
- Trial name
- NCT06766617
- Testing
- 75 gr Glucose
- Where
- Switzerland
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Prediabetes
Blood Sugar Take Care and Glucose Metabolism
This prospective international clinical trial is a two-arm, double-blind, randomized, placebo-controlled, parallel-group, multicenter study. 112 prediabetic subjects will be randomized to Blood Sugar Take Care or placebo.
- Trial name
- NCT01554020
- Testing
- Blood Sugar Take Care
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- NewChapter, Inc.
Healthy Adults
Safety and Tolerance of a Novel Three-Strain Probiotic in Healthy Adults
This Phase I \& II study evaluates the safety and tolerability of 8 weeks of daily supplementation with high-dose versus standard-dose of a novel three-strain probiotic.
- Trial name
- NCT07566884
- Testing
- Three-Strain Probiotic
- Where
- Ireland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pendulum Therapeutics
Hypoglycemia
Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D
This study is a randomized, placebo-controlled, double-blind, 2-treatment, 2-period, crossover comparison in a clinical research center (CRC) setting, followed by a randomized, placebo-controlled, double-blinded, 2-arm parallel…
- Trial name
- NCT03841526
- Testing
- Glucagon RTU Injection With Insulin Pump Reduction, Vehicle for Glucagon RTU Injection With Insulin Pump Reduction, Glugaon RTU Injection Without Insulin Pump Reduction
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Xeris Pharmaceuticals
Type 2 Diabetes Mellitus
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to demonstrate equivalent blood glucose control in patients with type 2 diabetes mellitus with insulin VIAject™ and regular human insulin as prandial insulin and to demonstrate an equivalent safety…
- Trial name
- NCT00542633
- Testing
- VIAject™, Regular Human Insulin
- Volunteers
- 472 people
- Sponsor
- Biodel
Diabetes
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Glargine U100 with Non-Insulin Antidiabetic Agents in Insulin-naive Subjects with Type 2…
- Trial name
- NCT06767735
- Testing
- GZR4, Insulin Glargine U100
- Where
- China
- Volunteers
- 580 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of Teneligliptin in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration and to evaluate the safety and efficacy of Teneligliptin…
- Trial name
- NCT02081599
- Testing
- Teneli (Teneligliptin), Insulin
- Where
- Japan
- Volunteers
- 148 people
- Sponsor
- Tanabe Pharma Corporation
Type 1 Diabetes
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
To examine the effects of different fixed pramlintide:insulin dose ratios in subjects with type 1 diabetes on postprandial plasma glucose concentrations
- Trial name
- NCT01708044
- Testing
- Pramlintide acetate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Metabolic Syndrome
NWT03 and Arterial Stiffness
Rationale: Subjects with the metabolic syndrome have an increased risk of developing cardiovascular disease and a twofold risk of developing hypertension.
- Trial name
- NCT02561663
- Testing
- NWT-03, an egg-white protein hydrolysate
- Where
- Netherlands
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Newtricious R&D BV
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Insulin Resistance - Type A, Insulin Resistance - Type B
A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance
A multicenter, open-label, single-arm study with regard to the efficacy and safety of empagliflozin in patients with refractory diabetes mellitus with insulin resistance
- Conditions
- Insulin Resistance - Type A, Insulin Resistance - Type B, Lipoatrophic Diabetes Mellitus, Insulin Resistance Syndrome
- Trial name
- EMPIRE-01 (NCT04018365)
- Testing
- Empagliflozin Tablets
- Where
- 5 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kobe University
Health Services Accessibility, Rural Health
Health Ahead Comparative Effectiveness Study
The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening on the path toward a fully automated screening…
- Conditions
- Health Services Accessibility, Rural Health, Medically Underserved Area, Preventive Health Services
- Trial name
- HACE (NCT07669168)
- Testing
- AI-Assisted Screening Interpretation (AI Reads), Human-Only Screening Interpretation
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- William Brandenburg, MD
Congenital Hyperinsulinism
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 (NCT04172441) or ZP4207-17109 (NCT03777176)…
- Trial name
- NCT03941236
- Testing
- dasiglucagon
- Where
- 10 sites in United States, Germany and 2 more
- Volunteers
- 42 people
- Sponsor
- Zealand Pharma
Glycemic Index of a Meal
Glycemic Response After Palaeolithic-type Meals
The objective of the study is to show post-prandial benefits of Palaeolithic-type meals as compared to a meal constructed along the lines of the WHO dietary recommendations.
- Trial name
- NCT01418573
- Testing
- Palaeolithic meal 1, Palaeolithic meal 2, Reference meal
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Obesity & Overweight, Circadian Rhythm Disorders
Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers
Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns.
- Conditions
- Obesity & Overweight, Circadian Rhythm Disorders, Gut Microbiota Modulation, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
- Trial name
- Shift2Health (NCT07440147)
- Testing
- Verum (A)
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- FH Joanneum Gesellschaft mbH
Metabolic Syndrome, Diabetes Mellitus, Type 2
Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies
Original research article entitled Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome by Madeline Gibas for consideration for publication in a clinical journal.
- Conditions
- Metabolic Syndrome, Diabetes Mellitus, Type 2, Pre Diabetes
- Trial name
- NCT03047447
- Testing
- Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Behavioral Health, Inc.
Type 2 Diabetes
24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine
The purpose of this study is to determine if twice-daily Lispro low mixture (75/25) will result in lower post prandial blood glucose readings versus once-daily glargine plus oral diabetic medications.
- Trial name
- NCT00551538
- Testing
- Lispro mix 75/25, Glargine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
Obesity, Metabolic Syndrome
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with obesity and metabolic syndrome.
- Trial name
- NCT05891834
- Testing
- INV-202
- Where
- 24 sites in Canada
- Volunteers
- 243 people
- Sponsor
- Inversago Pharma Inc.
Postprandial Hyperglycemia
Determination of the GI and II Values of Soft Drink and Soft Drink With Sugardown™
This study was a partly controlled laboratory-based study comparing the glycemic and insulinemic indices of 3 test meals containing soft drink alone or with SUGARDOWN™ (Galactomannan) in overweight adults.
- Trial name
- NCT03374501
- Testing
- Sugardown™, Soft drink
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Boston Therapeutics